Guide to SABCS 2025: ECOG-ACRIN research at the world’s largest breast cancer conference

Researchers affiliated with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will be active at the annual San Antonio Breast Cancer Symposium, scheduled for December 9–12, 2025. The presentations include a clinical trial of FDG-PET imaging for measuring treatment response, correlative studies from the landmark TAILORx trial in early breast cancer, the important role of immune cells in tumors, new data from the first trial to focus on Black women with early-stage breast cancer, and an update on TMIST, the large-scale randomized mammography trial.

Listed below are the presentation authors, titles, and links to logistical information. The text of the abstracts will be posted at 3:30 PM Central Time on Monday, November 24. 2025.

Primary Results from an FDG-PET Imaging Clinical Trial

• Late-Breaking Abstract RF4-06 – Jennifer M. Specht, MD (University of Washington/Fred Hutch Cancer Center) will present FDG-PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE: ECOG-ACRIN EA1183, during Rapid Fire Session 4.

TAILORx Correlative Studies

• Embargoed Late-Breaking Abstract GS1-08 – Part of the Official SABCS Press Program – Joseph A. Sparano, MD ( Mount Sinai Health System/The Tisch Cancer Institute) will present Multimodal AI Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence, during General Session 1.

• Late-Breaking Abstract RF3-01 – Roberto Salgado, MD, PhD (Peter MacCallum Cancer Centre) will present Clinical Outcomes of Invasive Lobular Carcinoma (ILC) Versus Non-Lobular Breast Cancer (NLC) Assessed by Expert Pathologists, an Artificial Intelligence (AI) CDH1 Classifier, and AI-Derived Tumor Microenvironment (TME) Biomarkers in TAILORx, during Rapid Fire Session 3.

• Abstract RF3-07 – Eleftherios (Terry) Mamounas, MD, MPH, FACS (AdventHealth Cancer Institute) will present A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer, during Rapid Fire Session 3.

Role of Immune Cells in Tumors

• Abstract GS1-04 – Sunil S. Badve, MD, FRCPath (Emory University) will present Tumor Infiltrating Lymphocytes (TILs) and Pathologic Complete Response (pCR) in Stage II/III HER2+ Breast Cancer Treated with Taxane, Trastuzumab, and Pertuzumab (THP): Secondary Results from the EA1181/CompassHER2 pCR Trial, during General Session 1.

• Abstract RF3-06 – Sunil S. Badve, MD, FRCPath (Emory University) will present Tumor Infiltrating Lymphocytes in Post-NACT Residual Tumors in ECOG-ACRIN EA1131 - Impact of Intrinsic Subtypes, during Rapid Fire Session 3.

• Abstract PD11-02 – Julia R. Dixon-Douglas, MD (Gustave Roussy) will present Artificial Intelligence for Tumor-Infiltrating Lymphocytes in Early-Stage TNBC: Results of a Collaborative Prospective TIL Validation Challenge, during Poster Spotlight Session 11.

First Study of Black Patients with Early Breast Cancer

• Abstract PS1-03-21 – Tarah J. Ballinger, MD (Indiana University) – will present Patient-reported Measures of Taxane-Induced Peripheral Neuropathy (TIPN) and Risk of Dose Reductions or Worsening Quality of Life in Black Women with Breast Cancer: Analysis from ECOG-ACRIN EAZ171, during Poster Session 1.

TMIST Large-Scale Mammography Trial in Progress

• Abstract PS5-07-19 – Study Chair Etta D. Pisano, MD, FACR (American College of Radiology) will present ECOG-ACRIN Tomosynthesis Mammographic Imaging Screening Trial (TMIST) - Update for 2025, during Poster Session 5.

The research listed above was supported by the National Cancer Institute, part of the National Institutes of Health.